Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H21NO3 |
Molecular Weight | 299.3642 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3OC
InChI
InChIKey=OROGSEYTTFOCAN-DNJOTXNNSA-N
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
Codeine is an opiate used to manage mild to moderate pain severe enough to require an opioid. Codeine is a selective agonist for the mu opioid receptor and has an affinity to delta and kappa-opioid receptors. In some countries, this drug is regulated under various narcotic control laws, because its chronic use can cause physical dependence. In others, it is available without a medical prescription in combination with paracetamol.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 |
6.1 µM [EC50] | ||
Target ID: P41145 Gene ID: 4986.0 Gene Symbol: OPRK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7885194 |
|||
Target ID: P41143 Gene ID: 4985.0 Gene Symbol: OPRD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7885194 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CAPITAL AND CODEINE Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Analgesic abuse, ureteric obstruction, and retroperitoneal fibrosis. | 1975 Apr 12 |
|
Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl. | 2001 |
|
Determination of opiates in serum, saliva and hair addicted persons. | 2001 |
|
Pharmacological control of cough. | 2001 Apr |
|
The use of compound 48/80 and codeine phosphate as positive controls for intradermal skin testing in dogs. | 2001 Apr |
|
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
LC method for the analysis of acetylsalicylic acid, caffeine and codeine phosphate in pharmaceutical preparations. | 2001 Apr |
|
LC method for the analysis of paracetamol, caffeine and codeine phosphate in pharmaceutical preparations. | 2001 Dec |
|
Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. | 2001 Feb |
|
Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo. | 2001 Jan |
|
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. | 2001 Jul |
|
Time of drug elimination in chronic drug abusers. Case study of 52 patients in a "low-step" detoxification ward. | 2001 Jun 15 |
|
[Information on preparations containing codeine]. | 2001 Jun 20 |
|
Codeine phosphate in children: time for re-evaluation? | 2001 Mar |
|
Expression and activity of cell-wall-degrading enzymes in the latex of opium poppy, Papaver somniferum L. | 2001 Mar |
|
GC-MS determination of heroin metabolites in meconium: evaluation of four solid-phase extraction cartridges. | 2001 Mar |
|
Evaluation of urinary dihydrocodeine excretion in human by gas chromatography-mass spectrometry. | 2001 Mar 5 |
|
Capillary electrophoresis-electrospray ionization ion trap mass spectrometry for analysis and confirmation testing of morphine and related compounds in urine. | 2001 May 4 |
|
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations. | 2001 May-Jun |
|
Nutritional effects of surgical and medical treatment for short bowel syndrome. | 2001 Nov-Dec |
|
Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays. | 2001 Oct |
|
Ropivacaine with or without clonidine improves pediatric tonsillectomy pain. | 2001 Oct |
|
Drug contamination of US paper currency. | 2001 Oct 1 |
|
Blind trials of an onsite saliva drug test for marijuana and opiates. | 2001 Sep |
|
Concentration ratios of codeine-to-morphine in plasma after a single oral dose (100 mg) of codeine phosphate. | 2001 Sep |
|
Pain control in medical abortion. | 2001 Sep |
|
Engineering novel biocatalytic routes for production of semisynthetic opiate drugs. | 2001 Sep |
|
Can standard open pediatric urological procedures be performed on an outpatient basis? | 2001 Sep |
|
Experience with urine drug testing by the Correctional Service of Canada. | 2001 Sep 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://online.lexi.com/lco/medguides/622452.pdf
Unknown
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175690
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
||
|
NDF-RT |
N0000175684
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
||
|
CFR |
21 CFR 862.3270
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
||
|
DEA NO. |
9050
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
||
|
WHO-ATC |
N02AJ09
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00318
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
100000079790
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
76-57-3
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
C171855
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
ALTERNATIVE | |||
|
200-969-1
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
5284371
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
m3718
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | Merck Index | ||
|
C77284
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
16714
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
DTXSID2020341
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
UX6OWY2V7J
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
236131
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
ALTERNATIVE | |||
|
1545976
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
3043
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
SUB127261
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
SUB13424MIG
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY | |||
|
UX6OWY2V7J
Created by
admin on Fri Dec 15 16:30:16 UTC 2023 , Edited by admin on Fri Dec 15 16:30:16 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE ACTIVE (PRODRUG)
METABOLITE ACTIVE (PRODRUG)
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)